Avanos Medical (NYSE:AVNS) Given Market Perform Rating at JMP Securities

Avanos Medical (NYSE:AVNS)‘s stock had its “market perform” rating reaffirmed by analysts at JMP Securities in a research report issued to clients and investors on Tuesday, Benzinga reports.

Separately, StockNews.com cut Avanos Medical from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. Three investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $31.00.

Avanos Medical Stock Performance

Shares of AVNS opened at $19.56 on Tuesday. The stock has a 50-day moving average of $19.22 and a two-hundred day moving average of $19.93. Avanos Medical has a one year low of $17.24 and a one year high of $26.56. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.47 and a current ratio of 2.28. The stock has a market cap of $897.80 million, a P/E ratio of -14.71 and a beta of 0.97.

Avanos Medical (NYSE:AVNS) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $0.19 EPS for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.02). Avanos Medical had a positive return on equity of 4.10% and a negative net margin of 9.15%. The firm had revenue of $166.10 million for the quarter, compared to analyst estimates of $162.90 million. During the same period in the prior year, the firm posted $0.27 EPS. The business’s revenue was up 4.3% compared to the same quarter last year. As a group, research analysts predict that Avanos Medical will post 1.38 EPS for the current year.

Insider Buying and Selling at Avanos Medical

In other Avanos Medical news, CFO Michael Greiner sold 8,000 shares of Avanos Medical stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $19.12, for a total transaction of $152,960.00. Following the completion of the transaction, the chief financial officer now owns 151,495 shares in the company, valued at approximately $2,896,584.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 3.94% of the company’s stock.

Hedge Funds Weigh In On Avanos Medical

A number of institutional investors have recently modified their holdings of AVNS. William Blair Investment Management LLC purchased a new position in shares of Avanos Medical during the 3rd quarter valued at about $22,134,000. Norges Bank purchased a new position in shares of Avanos Medical during the 4th quarter valued at about $7,016,000. RGM Capital LLC raised its stake in shares of Avanos Medical by 6.8% during the 3rd quarter. RGM Capital LLC now owns 2,951,691 shares of the company’s stock valued at $59,683,000 after buying an additional 189,017 shares during the last quarter. Foundry Partners LLC raised its stake in shares of Avanos Medical by 74.6% during the 4th quarter. Foundry Partners LLC now owns 371,029 shares of the company’s stock valued at $8,322,000 after buying an additional 158,473 shares during the last quarter. Finally, Kestrel Investment Management Corp purchased a new position in shares of Avanos Medical during the 4th quarter valued at about $3,265,000. Hedge funds and other institutional investors own 95.17% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.